Advisors
Industry Advisors
Burton G. Christensen, Ph.D.
Former EVP, Research, Theravance, Inc.; SVP, Chemistry, Merck & Co; inventor of imipenem, co-inventor of several other antibiotics.
Stephen Kaldor, Ph.D.
CEO, Ambrx; former CSO, Takeda, inventor of Viracept.
Lynn L. Silver, Ph.D.
LL Silver Consulting. Former Senior Investigator in infectious disease research, Merck and Co.
George Miller, Ph.D.
CSO, Blanca Pharmaceuticals; formerly CSO of Microcide; led the development of gentamicin; internationally recognized expert on aminoglycosides.
Seemon H. Pines, Ph.D.
Former SVP, Process Chemistry, Merck & Co. Recipient of Chairman's Award for the commercially viable synthesis of imipenem.
Clinical Advisors
William A. Craig, M.D.
University of Wisconsin, Madison
Jay Fishman, M.D.
MGH, Harvard Medical School
H. Shaw Warren, M.D.
MGH, Harvard Medical School
George L. Drusano, M.D.
Ordway Research Institute, Albany
Otto Cars, M.D.
Uppsala University Hospital, Uppsala, Sweden
Vance Fowler, M.D.
Duke University, Duke Clinical Research Institute
Henry F. "Chip" Chambers, M.D.
University of California San Francisco
Academic Advisors
Peter G. Schultz, Ph.D.
Genomics Institute of the Novartis Foundation
Floyd E. Romesberg, Ph.D.
The Scripps Research Institute
Stephen Hanessian, Ph.D.
The University of Montreal
Paul Tulkens, M.D.
Catholic University of Louvain, Belgium
Regulatory Advisors
Gino Girardi, M.D.
Former FDA clinical reviewer, anti-infectives division, CDER
Hilary Sheevers, Ph.D.
Former FDA drug safety reviewer, anti-infectives division, CDER
Bob Osterberg, Ph.D.
Former FDA drug safety reviewer, anti-infectives division, CDER
Seemon H. Pines, Ph.D.
Former head of Process Research, Merck
Elizabeth M. Vadas, Ph.D.
Former head of Pharmaceutical R&D, Merck-Frosst